ATOS earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -0.56. Updated 2026-07-23.
Atossa Therapeutics (ATOS) Research Hub
Atossa Therapeutics (ATOS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.51 USD (+4.58%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.56, market cap 0.02B. This hub links to the full technical, earnings and options research available for ATOS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.51 USD (+4.58%) |
| 52-week range | 1.73 USD – 2.97 USD |
| Trend regime | Range |
| 14-day RSI | 55.2 (Bullish) |
| Trailing P/E | -0.56 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for ATOS
Covered Call on ATOS: how it works, illustrative setup around the real 2.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ATOS: how it works, illustrative setup around the real 2.51 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ATOS: how it works, illustrative setup around the real 2.51 USD price, max profit/loss, breakeven and when to use it. Educational.
ATOS technical analysis: range, last 2.51 USD, RSI 55.2, 52w range 1.73 USD–2.97 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ATOS in?
Atossa Therapeutics (ATOS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ATOS in an uptrend or downtrend?
As of 2026-09-11, ATOS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ATOS's trailing P/E ratio?
ATOS's trailing P/E is -0.56, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does ATOS next report earnings?
ATOS is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -1.04 USD.